1-4 of 4
Changchun Du, BM, BS
Close
Sort by
Journal Articles

PI3K Signaling Pathway Activation Predicts Class I PI3K Inhibitor GDC-0941 Sensitivity in AML.

Xiaoju Max Ma, PhD, Changchun Du, BM, BS, Laura Sun, Xiaoyan Shi, Ph.D, Lori Friedman, David Dornan, Ph.D, Allen J. Ebens, PhD
Journal: Blood
Blood (2009) 114 (22): 1057.
https://doi.org/10.1182/blood.V114.22.1057.1057
Published: 2009
Journal Articles

The PI3K Inhibitor GDC-0941 Induces Growth Arrest and Apoptosis of Acute Myeloid Leukemia Cells.

Laura Sun, Leanne Berry, Changchun Du, BM, BS, Xiaoju Max Ma, Lily Shi, Bruno C. Medeiros, MD, Allen J. Ebens, PhD
Journal: Blood
Blood (2009) 114 (22): 3787.
https://doi.org/10.1182/blood.V114.22.3787.3787
Published: 2009
Journal Articles

The PI3K Inhibitor GDC-0941 Synergizes with Standard of Care Therapies to Induce Growth Inhibition and Apoptosis of Multiple Myeloma Cells.

Veerendra Munugalavadla, PhD, Leanne Berry, Changchun Du, BM, BS, Sanjeev Mariathasan, Dion Slaga, Laura Sun, Marta Chesi, Peter Leif Bergsagel, MD, Allen J. Ebens, PhD
Journal: Blood
Blood (2009) 114 (22): 3788.
https://doi.org/10.1182/blood.V114.22.3788.3788
Published: 2009
Journal Articles

CD40 Pathway Activation Status Predicts Response to CD40 Targeted Therapy in Diffuse Large b-Cell Lymphoma.

David Dornan, Ph.D, Bart Burington, Ph.D, Peng Yue, Ph.D, Xiaoyan Shi, Ph.D, Ranjana Advani, MD, Nancy Yu, Jeffrey T Lau, Shang-Fan Yu, Sven De Vos, MD, PhD, Stephen M Ansell, Andres Forero-Torres, MD, Zora Modrusan, Hartmut Koeppen, Teddy Yang, Changchun Du, BM, BS, Kristi Elkins, Andrew G. Polson, Rienk Offringa, Nancy Whiting, PharmD, BCOP, Allen J. Ebens, PhD
Journal: Blood
Blood (2009) 114 (22): 2721.
https://doi.org/10.1182/blood.V114.22.2721.2721
Published: 2009